GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Momenta Pharmaceuticals Inc (NAS:MNTA) » Definitions » Operating Margin %

Momenta Pharmaceuticals (Momenta Pharmaceuticals) Operating Margin % : -868.05% (As of Jun. 2020)


View and export this data going back to 2004. Start your Free Trial

What is Momenta Pharmaceuticals Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Momenta Pharmaceuticals's Operating Income for the three months ended in Jun. 2020 was $-57.38 Mil. Momenta Pharmaceuticals's Revenue for the three months ended in Jun. 2020 was $6.61 Mil. Therefore, Momenta Pharmaceuticals's Operating Margin % for the quarter that ended in Jun. 2020 was -868.05%.

Warning Sign:

Momenta Pharmaceuticals Inc operating margin has been in 5-year decline. The average rate of decline per year is -41.3%.

The historical rank and industry rank for Momenta Pharmaceuticals's Operating Margin % or its related term are showing as below:

MNTA' s Operating Margin % Range Over the Past 10 Years
Min: -1305.94   Med: -94.11   Max: 63.48
Current: -814.82


MNTA's Operating Margin % is not ranked
in the Drug Manufacturers industry.
Industry Median: 6.075 vs MNTA: -814.82

Momenta Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was -41.30% per year.

Momenta Pharmaceuticals's Operating Income for the three months ended in Jun. 2020 was $-57.38 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2020 was $-245.19 Mil.


Momenta Pharmaceuticals Operating Margin % Historical Data

The historical data trend for Momenta Pharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Momenta Pharmaceuticals Operating Margin % Chart

Momenta Pharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -94.18 -68.17 -66.64 -216.33 -1,305.94

Momenta Pharmaceuticals Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,248.05 -935.61 -1,067.55 -457.51 -868.05

Competitive Comparison of Momenta Pharmaceuticals's Operating Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Momenta Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Momenta Pharmaceuticals's Operating Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Momenta Pharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Momenta Pharmaceuticals's Operating Margin % falls into.



Momenta Pharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Momenta Pharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2019 is calculated as

Operating Margin %=Operating Income (A: Dec. 2019 ) / Revenue (A: Dec. 2019 )
=-311.701 / 23.868
=-1,305.94 %

Momenta Pharmaceuticals's Operating Margin % for the quarter that ended in Jun. 2020 is calculated as

Operating Margin %=Operating Income (Q: Jun. 2020 ) / Revenue (Q: Jun. 2020 )
=-57.378 / 6.61
=-868.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Momenta Pharmaceuticals  (NAS:MNTA) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Momenta Pharmaceuticals Operating Margin % Related Terms

Thank you for viewing the detailed overview of Momenta Pharmaceuticals's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Momenta Pharmaceuticals (Momenta Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
301 Binney Street, Cambridge, MA, USA, 02142
Momenta is a biotechnology company focused on the characterization and development of innovative drugs in autoimmune diseases. Its legacy business includes complex generic versions of MS drug Copaxone and anticoagulant Lovenox, and it receives royalties for these products through a partnership with Novartis. While a biosimilar version of Eylea is in the pipeline, Momenta terminated future development in generics/biosimilars in 2018. Several innovative drugs, including nipocalimab, M254, and M230, are in development to treat rare autoimmune diseases.
Executives
Bruce Downey director
Alejandra Carvajal officer: Chief Legal Officer C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139
Jose-carlos Gutierrez-ramos director C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Georges Gemayel director 550 HILLS DRIVE, BEDMINSTER NJ 07921
Elizabeth Stoner director C/O MOMENTA PHARMACEUTICALS, INC. 675 WEST KENDALL STREET CAMBRIDGE MA 02142
Santiago Arroyo officer: SVP, Chief Medical Officer C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Young Kwon officer: Chief Financial & Bus. Officer C/O MOMENTA PHARMACEUTICALS INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Ian Fier officer: Chief Mfg and Program Officer C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Jo Ann Beltramello officer: Chief HR and Inf. Officer C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Jane F Barlow director 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Anthony M. Manning officer: Chief Scientific Officer C/O PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Donna Roy Grogan director 1133 OLD QUEEN ANNE ROAD, CHATHAM MA 02633
Agnieszka Cieplinska officer: Chief Accounting Officer (PAO) C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Craig A Wheeler director, officer: President & CEO